Pharmacokinetics of Etoricoxib in Patients with Renal Impairment
| Autor: | Peggy H. Wong, Catherine Z. Matthews, Josee Cote, Marshall Sack, Nancy G. B. Agrawal, Eric Woolf, Arturo G. Porras, Richard Robson, Leslie A. Geer, Suzanne K. Swan, W. F. Kline, Ralph S. Mazenko, Kevin J. Petty, Harry Alcorn, Keith Gottesdiener, Meehung Cho, Thomas Marbury, Jack W. Moncrief, Jules I. Schwartz |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Metabolic Clearance Rate Pyridines medicine.medical_treatment Urology Administration Oral Biological Availability Renal function urologic and male genital diseases Etoricoxib Pharmacokinetics Renal Dialysis Oral administration medicine Humans Cyclooxygenase Inhibitors Pharmacology (medical) Sulfones Dosing Aged Pharmacology Clinical Trials as Topic biology business.industry Middle Aged medicine.disease Surgery Area Under Curve biology.protein Kidney Failure Chronic Female Cyclooxygenase Hemodialysis business Half-Life Protein Binding medicine.drug Kidney disease |
| Zdroj: | The Journal of Clinical Pharmacology. 44:48-58 |
| ISSN: | 0091-2700 |
| Popis: | The effect of renal insufficiency on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, was examined in 23 patients with varying degrees of renal impairment (12 moderate [creatinine clearance between 30 and 50 mL/min/1.73 m2], 5 severe [creatinine clearance below 30 mL/min/1.73 m2], and 6 with end-stage renal disease requiring hemodialysis) following administration of single 120-mg oral doses of etoricoxib. Even the most severe renal impairment was found to have little effect on etoricoxib pharmacokinetics. The low recovery of etoricoxib in dialysate (less than 6% of the dose) supports that hemodialysis also has little effect on etoricoxib pharmacokinetics, and binding of etoricoxib to plasma proteins was generally unaffected by renal disease. Single doses of etoricoxib were generally well tolerated by patients with renal impairment. Based on pharmacokinetic considerations, dosing adjustments are not necessary for patients with any degree of renal impairment. However, because patients with advanced renal disease (creatinine clearance below 30 mL/min/1.73 m2) are likely to be very sensitive to any further compromise of renal function, and there is no long-term clinical experience in these patients, the use of etoricoxib is not recommended in patients with advanced renal disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text